Loading...

Humacyte, Inc.

HUMAWNASDAQ
Healthcare
Biotechnology
$0.44
$0.03(7.37%)

Humacyte, Inc. HUMAW Peers

See (HUMAW) competitors and their performances in Stock Market.

Peer Comparison Table: Biotechnology Industry

Detailed financial metrics including price, market cap, P/E ratio, and more.

SymbolPriceChange %Market CapP/E RatioEPSDividend Yield
HUMAW$0.44+7.37%353.1M-0.14-$3.16N/A
VRTX$457.03+1.08%117.4B-119.02-$3.84N/A
REGN$547.74+2.40%58.1B13.92$39.35+0.16%
SGEN$228.74-0.07%43.2B-57.19-$4.00N/A
ALNY$329.77+2.39%43B-156.28-$2.11N/A
ARGX$545.11+0.49%33.3B33.26$16.39N/A
BNTX$108.26+0.70%26B-29.57-$3.66N/A
RPRX$36.19+0.86%20.3B14.77$2.45+2.40%
BGNE$184.71+0.49%20.2B-22.55-$8.19N/A
DNA-WT$0.27-2.76%18.7BN/AN/AN/A
Showing 1 to 10 of 100 results
1

Stock Comparison

Select a stock to compare (requires JavaScript). Showing default comparison.

HUMAW vs VRTX Comparison

HUMAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HUMAW stands at 353.1M. In comparison, VRTX has a market cap of 117.4B. Regarding current trading prices, HUMAW is priced at $0.44, while VRTX trades at $457.03.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HUMAW currently has a P/E ratio of -0.14, whereas VRTX's P/E ratio is -119.02. In terms of profitability, HUMAW's ROE is +2.86%, compared to VRTX's ROE of -0.06%. Regarding short-term risk, HUMAW is more volatile compared to VRTX. This indicates potentially higher risk in terms of short-term price fluctuations for HUMAW.

Stock Price Comparison

Loading...

Frequently Asked Questions

;